IDEX Fundamental Analysis - IDEX BIOMETRICS ASA

Fundamental Rating

Overall IDEX gets a fundamental rating of 1 out of 10. We evaluated IDEX against 48 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of IDEX have multiple concerns. IDEX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

IDEX had negative earnings in the past year.

In the past year IDEX has reported a negative cash flow from operations.

In the past 5 years IDEX always reported negative net income.

IDEX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -144.01%, IDEX is not doing good in the industry: 93.62% of the companies in the same industry are doing better.

IDEX's Return On Equity of -9147.92% is on the low side compared to the rest of the industry. IDEX is outperformed by 91.49% of its industry peers.

		Industry Rank	Sector Rank
ROA	-144.01%
ROE	-9147.92%
ROIC	N/A

ROA(3y)-119.85%

ROA(5y)-118.87%

ROE(3y)-228.17%

ROE(5y)-196.92%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IDEX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IDEX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for IDEX has been increased compared to 1 year ago.

IDEX has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, IDEX has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -59.33, we must say that IDEX is in the distress zone and has some risk of bankruptcy.

IDEX's Altman-Z score of -59.33 is on the low side compared to the rest of the industry. IDEX is outperformed by 91.49% of its industry peers.

A Debt/Equity ratio of 12.58 is on the high side and indicates that IDEX has dependencies on debt financing.

IDEX has a Debt to Equity ratio of 12.58. This is amonst the worse of the industry: IDEX underperforms 91.49% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	12.58
Debt/FCF	N/A
Altman-Z	-59.33

ROIC/WACCN/A

WACC8.34%

2.3 Liquidity

A Current Ratio of 1.65 indicates that IDEX should not have too much problems paying its short term obligations.

IDEX has a Current ratio of 1.65. This is comparable to the rest of the industry: IDEX outperforms 48.94% of its industry peers.

IDEX has a Quick Ratio of 1.65. This is a bad value and indicates that IDEX is not financially healthy enough and could expect problems in meeting its short term obligations.

IDEX has a worse Quick ratio (0.54) than 87.23% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.65
Quick Ratio	0.54

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IDEX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.62%, which is quite impressive.

IDEX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -82.47%.

The Revenue has been growing by 14.73% on average over the past years. This is quite good.

EPS 1Y (TTM)70.62%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%74.23%

Revenue 1Y (TTM)-82.47%

Revenue growth 3Y-33.35%

Revenue growth 5Y14.73%

Sales Q2Q%-72.04%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year49.24%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IDEX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Based on the Price/Forward Earnings ratio of 6.88, the valuation of IDEX can be described as very cheap.

Based on the Price/Forward Earnings ratio, IDEX is valued cheaply inside the industry as 85.11% of the companies are valued more expensively.

Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, IDEX is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.88

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IDEX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IDEX BIOMETRICS ASA

OSL:IDEX (7/11/2025, 7:00:00 PM)

3.574

-0.03 (-0.71%)

Chartmill FA Rating

GICS SectorInformation Technology

GICS IndustryGroupTechnology Hardware & Equipment

GICS IndustryElectronic Equipment, Instruments & Components

Earnings (Last)05-21 2025-05-21

Earnings (Next)08-15 2025-08-15

Inst Owners1.4%

Inst Owner ChangeN/A

Ins Owners0.62%

Ins Owner ChangeN/A

Market Cap62.71M

Analysts82.86

Price Target13.24 (270.45%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.88
P/S	10.86
P/FCF	N/A
P/OCF	N/A
P/B	43.2
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.29

EYN/A

EPS(NY)0.52

Fwd EY14.53%

FCF(TTM)-7.68

FCFYN/A

OCF(TTM)-7.69

OCFYN/A

SpS0.33

BVpS0.08

TBVpS-0.23

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-144.01%
ROE	-9147.92%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-119.85%

ROA(5y)-118.87%

ROE(3y)-228.17%

ROE(5y)-196.92%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score1

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	12.58
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.65
Quick Ratio	0.54
Altman-Z	-59.33

F-Score1

WACC8.34%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)70.62%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%74.23%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-82.47%

Revenue growth 3Y-33.35%

Revenue growth 5Y14.73%

Sales Q2Q%-72.04%

Revenue Next Year49.24%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y24.99%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year1659.05%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y58.41%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y58.08%

OCF growth 3YN/A

OCF growth 5YN/A

IDEX BIOMETRICS ASA (IDEX.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens